Coherus Oncology, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Coherus Oncology executed a Sales Agreement with Leerink Partners LLC on August 28, 2026, establishing an at-the-market (ATM) offering program to sell up to $50,000,000 of common stock ($0.0001 par value). Leerink Partners acts as sole sales agent with a 3.0% commission on gross proceeds. The offering is registered under Form S-3 (File No. 333-291520), effective December 8, 2025, with prospectus supplement filed August 28, 2026. The program permits sales at any time, subject to Company placement notices and customary market conditions.
Why this rating
ATM offering is material financing tool for $81.9M-cap biotech—$50M represents 61% of market value. Provides capital flexibility without fixed price dilution risk; positive for runway. Competitive risk: dilution unknown until shares sold.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.38 ▼ 0.58% | at our read · backfill $1.39 |
The stock had already moved +0.58% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.